ABSTRACT
Progressive emphysema is an important element of chronic obstructive pulmonary disease (COPD). Except for α1-antitrypsin (AAT) replacement, disease modifying therapies do not exist. We show that Chymotrypsin-like Elastase 1 (CELA1) is required for emphysema progression using murine lung injury and aging models with correlative human data. CELA1 is expressed in distal lung epithelial cells during lung development, is absent in mature human lung, and is re-expressed in mouse and human AT2 cells after injury. Human CELA1 mRNA levels increase with age, and smoking reduces AAT neutralization of CELA1. CELA1 binding to healthy human lung tissue is increased with biaxial strain. Anti-CELA1 KF4 monoclonal antibody detects residues 53-78 of hCELA1 and inhibits ∼30% of lung elastolytic activity in COPD lung. We propose a CELA1-based risk model in which (1) CELA1 expression increases with age, (2) AAT neutralization of CELA1 is reduced by smoking, and (3) CELA1 binding to lung elastin increases with tissue distortion leading to airspace destruction and loss of lung function. CELA1 may represent a therapeutic target to prevent distal airspace destruction in COPD.
ONE SENTENCE SUMMARY We find that Chymotrypsin-like Elastase 1 (CELA1) mediates progressive airspace destruction in mouse emphysema models, that human lung CELA1 expression and binding to lung matrix are associated with known emphysema risk factors, and that the KF4 anti-CELA1 monoclonal antibody inhibits elastolytic activity in human COPD lung.
Competing Interest Statement
Patents for use of anti-CELA1 therapies for alpha-1 antitrypsin-deficient emphysema and COPD.
Funding Statement
Funding: A1 Foundation Research Award 498262 (Varisco), NHBLI R01141229 (Varisco), NHLBI K08HL131261 (Varisco).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human tissue utilized under a waiver from the CCHMC IRB (2016-9641)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Single Cell mRNA-seq data and monoclonal antibody validation data added.
Data Availability
After peer-review publication, the data in this manuscript will be made available upon request.
